Tyra Biosciences Overview
Latest ROE for Tyra Biosciences: -42.01% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-42.01%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Tyra Biosciences (TYRA) currently reports a ROE of -42.01%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Tyra Biosciences's ROE history and peer comparisons.
Tyra Biosciences's ROE of -42.01% is lower than the Healthcare sector average of 11.15%. That is roughly 476.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Tyra Biosciences's current -42.01% should be judged against Healthcare norms (sector average: 11.15%) and against TYRA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -42.01%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Tyra Biosciences, and consider following TYRA for alerts when major investors trade the stock.
Tyra Biosciences is classified in the Healthcare sector. On ROE, it currently shows -42.01% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TYRA with unrelated industries.
